Tirzepatide

Tirzepatide has Phase 3 RCT-grade clinical evidence for Obesity. Off-label / exploratory data exists for 75 additional indications (Endometrial Cancer; Obesity & Overweight). 6 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.

Tirzepatide

Research Evidence

Evidence shape

Tirzepatide has Phase 3 RCT-grade clinical evidence for Obesity. Off-label / exploratory data exists for 75 additional indications (Endometrial Cancer; Obesity & Overweight). 6 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.

Depthhow much
218 registered trials
73 completed · 44 with posted results · 135 recruiting / active · combined n=19542
Breadthhow many areas
89 indications mapped
10 with results · 75 thin / exploratory · 1 animal-only · 62 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
26 blinded with results · 12 distinct sponsors · AE rows aggregated from 42 trials · 111 linked publications on registered trials
Breadth and depth242 rows captured
Human
direct clinical signal
218
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
Midwest Peptide
Mission, KS, USA
2026 mg
$103.99
$0.051/mg
2
Nextgenpeps
US
10 mg
$0.97
$0.097/mg
3
High Purity Peptides
HK
400 mg
$130.00
$0.325/mg
4
Evolve BioPep
US
600 mg
$675.00
$1.13/mg
5
Trustedpeps
US
30 mg
$39.95
$1.33/mg
6
Sentinel Valor
US
400 mg
$599.00
$1.5/mg

price offers can be sorted by column

1-6 of 84

Dosing & Protocol

How Tirzepatide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 73
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

73 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Typical dose
5 mg5 mg – 15 mg
2 mg
3 mg
5 mg
10 mg
15 mg
Frequency
weekly
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 5 mg–15 mg weekly subQ (3 sources).

3 sources
Anecdotal
Community-reported real-world use · n = 23
Typical dose
2.5 mg2 mg – 10 mg
typical
2 mg
3 mg
5 mg
10 mg
15 mg
distribution of 7 reported doses · darker = more reports
By reported cadence
Schedule unstated2.5 mg (2 mg–10 mg) · n=7
Frequency
unspecified
Timing
unspecified
Route
subQ
Cycle
unspecified

Reported doses span 2 mg–10 mg, most commonly 2.5 mg; most posters do not state a schedule.

6 sources

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO. Discontinue if pancreatitis is suspected.
  • • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necess…
  • • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue MOUNJARO if suspected and promptly seek medical advice.
  • • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
  • • Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. MOUNJARO is not recommended in patients with severe gastroparesis.
  • • Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Monitor…
  • • Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
  • • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedur…
Contraindications
  • • MOUNJARO is contraindicated in
  • • patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in
  • • patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] . Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity rea…
  • • patients with Multiple Endocrine Neoplasia syndrome type 2. Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.
Drug interactions
  • • MOUNJARO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.2)

Peptide feedback

0 forum replies

Live community discussion for Tirzepatide, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.